Tag: Health

Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform

by jezzabellemente, posted in Uncategorized

ALBANY, N.Y., March 24 (Bernama-GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility as well as enhancements to its proprietary platform for cell line development.

The Glasgow, UK, site is well known throughout the industry for its more than 25 years of experience with formulation, lyophilization development and sterile fill-finish capabilities, including ADCs and other highly potent products. The current expansion is expected to be completed by early 2027. The investment will add an Annex 1 compliant isolator-based vial filling line and lyophilizer. Once complete, Glasgow will be able to fill batches up to 20,000 vials and will be well‑positioned to support future small‑scale commercial fills.

“This expansion in Glasgow comes as Curia is nearing completion of our significant expansion in our commercial drug product facility in Albuquerque, NM,” said Ron Aungst, VP, Drug Product Business Unit Operations. “Curia has already secured crucial equipment with long lead times to help the Glasgow expansion project stay on track, and we do not anticipate any disruption to current operations during the expansion.”

Curia’s clinical drug substance development capabilities have also been enhanced with improvements to the company’s cell line development (CLD) platform. The CLD offering at Curia’s Hopkinton, MA facility has been enhanced to incorporate IP-free semi-targeted integration technology that results in 6-fold higher titers compared to random integration technology. Curia’s stable platform, CHO-GSN®, was derived from the same parental cell line as its transient platform, TunaCHO®, allowing partners to efficiently scale-up from discovery to GMP.

“Our biologics division has always had end-to-end capabilities, and we are excited to offer a cell line that makes it more cost-efficient and faster to advance partners through early-stage clinical manufacturing,” said Jamie Grabowski, President, Research & Development. “With biotech-friendly licensing terms, reengineered cell line will be a critical component of successfully guiding partners on their path to commercialization.”

About Curia
Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20+ global sites and 3,100 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our offerings in small molecule, generic APIs and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

SOURCE: Curia Global, Inc.

MEDICAL KOREA 2026 TO SPOTLIGHT FUTURE OF AI-POWERED HEALTHCARE

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, March 3 (Bernama) — Medical Korea 2026, the 16th Global Healthcare & Medical Tourism Conference, will take place from March 19 to 22 at COEX in Seoul under the theme “AI-Powered Global Healthcare: Bringing the Future and the World Closer”.

Hosted by the Ministry of Health and Welfare and organised by the Korea Health Industry Development Institute (KHIDI), the conference will bring together global healthcare leaders, policymakers, and industry experts to discuss the future of artificial intelligence (AI)-powered healthcare and cross-border medical services.

Since its launch in 2010, Medical Korea has provided a platform for global dialogue on healthcare innovation and medical tourism, with this year’s event focusing on how AI is influencing healthcare delivery, digital transformation and international medical collaboration.

“Medical Korea 2026 will bring together global leaders and experts to address the latest trends and key issues in AI-driven healthcare. Through AI-powered innovation, the conference aims to strengthen global collaboration and bring the future of healthcare closer,” said KHIDI Director of the Department of Global Healthcare Business (Inbound), Andy Hong.

According to a statement, the programme includes an Opening Ceremony, eight Conference Sessions, Business Meetings, G2G Meetings, an Exhibition, FAM Tours, and the Medical Korea Gala Dinner.

At the Opening Ceremony, keynote speeches will be delivered by the Ministry of Health and Welfare Director General for Healthcare Industry Policy, Eun-Young Jung and Marx Advisory Chief Executive Officer, Edward Marx.

Meanwhile, the Conference Sessions will feature more than 40 domestic and international speakers discussing AI-driven healthcare innovation, medical tourism strategies, digital health trends and developments in AI-based medical technologies.

Business Meetings will provide structured networking opportunities for overseas patient attraction and international expansion, while G2G Meetings will facilitate discussions on healthcare and medical tourism cooperation between governments and related organisations.

The Exhibition will operate through three pavilions highlighting global healthcare collaboration, the competitiveness of Korea’s medical services industry and the Medical Korea platform, offering an overview of international medical capabilities and partnership opportunities.

— BERNAMA

Eyexora Establishes Co-Headquarters in Singapore to Accelerate Growth Across Asia-Pacific

by jezzabellemente, posted in Uncategorized

SINGAPORE, Nov 6 (Bernama-BUSINESS WIRE) — Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced the establishment of its co-headquarters in Singapore, marking a major milestone in the company’s global expansion and deepening its commitment to advancing eye health worldwide. Eyexora’s seed financing was led by ClavystBio, a global life sciences investor based in Singapore, and its initial programs have been in-licensed from the Singapore Eye Research Institute (SERI).

The new Singapore headquarters will serve as a gateway to Eyexora’s growing activities across the Asia-Pacific region, supporting clinical development, research collaborations, and regional partnerships. This expansion further strengthens Eyexora’s collaboration with the Singapore Eye Research Institute (SERI), a long-standing partner in ophthalmic innovation.

Eyexora’s Singapore operations will be instrumental in driving the company’s mission to develop transformative, accessible treatments for patients with vision-threatening diseases, while advancing scientific collaboration in one of the world’s most dynamic healthcare innovation hubs.

“Singapore has become a global center for ophthalmic research and innovation, and we are proud to deepen our presence here,” said Theresa Heah, M.D., M.B.A., Chief Executive Officer and Vice Chair of the Board, Eyexora. “This new co-headquarters positions Eyexora at the heart of Asia-Pacific’s biomedical ecosystem and strengthens our collaboration with SERI. Together, we are accelerating the development of breakthrough therapies that can improve vision and quality of life for patients around the world.”

“This milestone reflects our vision to build a truly global ophthalmic company,” said William J. Link, Ph.D, Chairman of the Board at Eyexora. “Singapore’s strong research infrastructure and commitment to innovation make it an ideal base for expanding Eyexora’s partnerships and advancing the next generation of eye care solutions.”

“Eyexora’s new co-headquarters are a testament to Singapore’s leadership in ophthalmology research and clinical delivery, and position as a global life sciences hub,” said Khoo Shih, Ph.D, CEO, ClavystBio. “At ClavystBio, we are excited to partner seasoned leaders like Theresa, William and their team to accelerate meaningful innovations and make global health impact.”

Last month Eyexora announced the launch of its second spoke company, Y.ora Vision, Inc., focused on developing next-generation ophthalmic medical devices for glaucoma. The company’s creation, complementing initial spoke company, Serenora Therapeutics, Inc., underscores Eyexora’s commitment to building a global ecosystem of specialized ventures that advance innovation across key therapeutic areas in ophthalmology.

Eyexora’s Singapore co-headquarters complements its U.S. base in New York, and will anchor the company’s Asia-Pacific operations, including clinical, scientific, and strategic functions, as it continues to grow its global footprint.

About Eyexora

Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. By centralizing scientific, clinical, regulatory, and commercial expertise, Eyexora advances a diversified pipeline of therapies and devices through focused subsidiaries, to reduce risk, improve efficiency, and scale impact. Founded by leaders with decades of ophthalmology experience and a track record of more than 30 successful company and product launches, Eyexora partners with clinician-scientists and research institutes worldwide to bring transformative eye care solutions to patients faster and smarter. For more information, visit www.eyexora.com.

About ClavystBio

ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Asia. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. For more information, please visit https://www.clavystbio.com/ and follow us on LinkedIn.

About Singapore Eye Research Institute (SERI)

Established in 1997, SERI is Singapore’s national research institute for ophthalmic and vision research. SERI’s mission is to conduct high-impact eye research that prevents blindness, low vision, and major eye diseases common to Singaporeans and Asians. Over the last decade, SERI has conducted landmark research projects that have led to tangible outcomes, patient benefits, and success stories. It has paved the way for significant improvements in how eye diseases are treated and prevented, not just for Singaporeans or Asians, but on a global scale.

At its inception, SERI saw a national remit in ophthalmic and vision research, and till today, SERI ensures that its facilities and resources are open to researchers across Singapore so that the greatest benefit may be obtained from what is a relatively small clinical ophthalmology catchment area in Singapore.

SERI has grown from a founding team of five in 1997 to a faculty of more than 253 staff, encompassing clinician scientists, scientists, research fellows, PhD students and support staff. This makes SERI one of the largest research institutes in Singapore, as well as the largest eye research institute in the Asia Pacific region. SERI has also over 255 adjunct faculties from various eye departments, biomedical institutes, and tertiary centres in Singapore. SERI has published an impressive array of 5,942 scientific papers and has secured external peer-reviewed competitive grants worth more than $473 million. As of December 2024, SERI’s faculty has been awarded with more than 1,425 national and international prizes and filed 188 patents.

As the research institute of the SNEC, and directly affiliated to the Yong Loo Lin School of Medicine, National University of Singapore, as well as the Duke-NUS Medical School, SERI undertakes vision research in collaboration with local clinical ophthalmic centres and biomedical research institutions, as well as major eye centres and research institutes throughout the world.

SERI ranks first globally in terms of eye publications per capita, far ahead of the US, UK, and Japan. With its impressive publication track record, SERI is comparable to renowned eye institutes, both regionally and internationally. Please see www.seri.com.sg.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20251104717799/en/

Contact

Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source : Eyexora

SOUNDHEALTH TO SHOWCASE AI-POWERED AIRWAY SCREENING APP AT WORLD SLEEP 2025

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, Sept 19 (Bernama) — SoundHealth, a medical technology company specialising in artificial intelligence (AI) solutions for respiratory health, will debut its groundbreaking AI-powered mobile platform, Airway, at World Sleep 2025 in Singapore this September.

The smartphone-based tool is designed to screen for obstructive sleep apnoea and sleep-disordered breathing in both children and adults. The presentation will be delivered by a team of physicians and experts, including SoundHealth founder and chief executive officer, Paramesh Gopi.

“We believe the Airway app represents a significant breakthrough in accessible airway diagnostics. By putting a non-invasive, accurate screening tool directly into the hands of clinicians and patients, we are entering a new frontier in digital health,” he said in a statement.

Meanwhile, orthodontics and dental sleep medicine expert Dr Eric Phelps said the technology could transform early detection of airway and sleep-breathing disorders, while the app provides a safe, scalable and objective tool to screen patients across all ages, expanding access to diagnosis beyond traditional clinical settings.

Airway is described as the first mobile platform that enables accurate sinonasal and airway function assessment without relying on traditional imaging methods such as cone beam computed tomography (CBCT).

The application leverages a smartphone’s camera and microphone to provide a non-invasive and radiation-free solution for large-scale screening.

The system works by capturing 3D facial scans to extract craniofacial landmarks predictive of nasal dimensions, allowing for a virtual reconstruction of airway structures, and also analyses voice recordings to measure speech resonance in different positions, producing a “Voice Nasal Flow Index” sensitive to posture-related congestion and obstruction.

According to validation studies, the platform demonstrated 95 per cent accuracy when compared with clinical CT scans for key nasal airway parameters. It generates three main scores—upper airway susceptibility, lower airway resistance and the Voice Nasal Flow Index—combined into an overall “Airway Health Score”.

The app is designed for scalable use in schools, dental practices and sleep clinics, offering early detection of airway dysfunctions that may affect craniofacial development, orthodontic planning and sleep quality.

— BERNAMA

KFSHRC Saves Saudi 7-Year-Old Through Cross-Border Heart Transplant with UAE Donor Organ

by jezzabellemente, posted in Uncategorized

RIYADH, Saudi Arabia, Aug 22 (Bernama-GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed a life-saving heart transplant on a 7-year-old Saudi child using an organ donated by a brain-dead donor in Abu Dhabi, United Arab Emirates.

The complex procedure was made possible through seamless cross-border cooperation between the Saudi Center for Organ Transplantation and the UAE’s National Program for Donation and Transplantation of Human Organs and Tissue (HAYAT), with full consent from the donor’s family and all regulatory approvals in place.

This cooperation involved precise medical and logistical coordination, starting with the organ extraction, followed by air transportation to Riyadh, and concluding with the preparation of operating theaters in record time. The transplantation was performed within a critically time-sensitive window, ultimately saving the life of a child who had no other treatment options available.

The medical team at KFSHRC performed the transplantation on the child, who was suffering from advanced heart failure due to a complex congenital heart defect. After exhausting all available treatment options—including medications, respiratory support, and pacemaker implantation—without any significant improvement, the child was placed on the urgent transplant list.

Time is a critical factor in heart transplant operations. According to medical standards, the period between removing the heart from the donor and transplanting it into the patient must not exceed five hours to ensure transplant success. This time constraint creates significant logistical challenges in addition to the complex medical procedures, particularly when the brain-dead donor is located in another region within the Kingdom or overseas. In such circumstances, every minute of delay becomes crucial to the operation’s success.

The KFSHRC Heart Centre is recognized as one of the world’s leading cardiac centers, having achieved exceptional milestones including the world’s first fully robotic heart transplant and robotic artificial heart pump implantation without chest incision. These unprecedented medical breakthroughs demonstrate the Kingdom’s leadership in complex cardiac surgery.

KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centers for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. It was included in the world’s best 250 hospitals and in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.

For more information, visit http://www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/aaf4d900-7f18-4871-9809-29e19875c14a

SOURCE: King Faisal Specialist Hospital & Research Centre